- Home
- V vs AZN Comparison
V vs AZN Comparison
Compare V & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | V | AZN |
|---|---|---|
| Founded | 1958 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.8B | 250.7B |
| IPO Year | 2007 | 1995 |
Fundamental Metrics
Financial Performance| Metric | V | AZN |
|---|---|---|
| Price | $385.90 | $159.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 40 | 12 |
| Target Price | ★ $419.36 | $206.91 |
| AVG Volume (30 Days) | ★ 5.0M | 2.4M |
| Earning Date | 10-27-2026 | 10-30-2026 |
| Dividend Yield | 0.71% | ★ 2.03% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $21,846,000,000.00 | N/A |
| Revenue This Year | $14.39 | $7.52 |
| Revenue Next Year | $10.99 | $6.16 |
| P/E Ratio | ★ $30.09 | $31.91 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $293.89 | $80.48 |
| 52 Week High | $385.57 | $212.71 |
Technical Indicators
Market Signals| Indicator | V | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 67.18 | 44.42 |
| Support Level | $358.40 | $154.89 |
| Resistance Level | $385.57 | $169.77 |
| Average True Range (ATR) | 6.32 | 2.79 |
| MACD | 1.76 | -0.43 |
| Stochastic Oscillator | 99.22 | 31.09 |
Price Performance
Historical ComparisonAbout V Visa Inc.
Visa is the largest payment processor in the world. In fiscal 2025, it processed almost $17 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.